E Fund Management (Hong Kong) Co., Ltd. I Mab Transaction History

E Fund Management (Hong Kong) Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$8.27 - $18.43 $187,447 - $417,734	-22,666 Closed	0 $0
Q1 2022 Apr 12, 2022	BUY	$12.54 - $46.93 $165,164 - $618,115	13,171 Added 138.72%	22,666 $318,000
Q4 2021 Feb 07, 2022	BUY	$45.28 - $74.5 $55,649 - $91,560	1,229 Added 14.87%	9,495 $450,000
Q2 2021 Jul 27, 2021	BUY	$47.86 - $83.95 $395,610 - $693,930	8,266 New	8,266 $694,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of E Fund Management (Hong Kong) Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management (Hong Kong) Co., Ltd. with notifications on news.